

**Appendix 6 (as supplied by the authors): Methodological quality of randomized controlled trials of rapid-acting insulin analogues in type 2 diabetes.**

| Study*   | Jadad score for: |                    |                             | Total<br>Jadad<br>score | Allocation<br>Concealment<br>? | Blinding<br>of<br>Outcome<br>Assessor? | Intent-to-<br>Treat<br>analysis? | Number<br>of<br>Patients | Dropouts<br>N (%) |
|--|------------------|--------------------|-----------------------------|-------------------------|--------------------------------|--|----------------------------------|--------------------------|-------------------|
|  | Randomization    | Double<br>Blinding | Withdrawals<br>and Dropouts |                         |                                |  |                                  |                          |                   |
| Altuntas <i>et al.</i> ,<br>2003 <sup>49</sup> | 1                | 0                  | 1                           | 2                       | Unclear                        | NR                                     | Yes                              | 60                       | 0                 |
| Anderson <i>et al.</i> ,<br>1997 <sup>35</sup> | 1                | 0                  | 0                           | 1                       | Unclear                        | NR                                     | Yes                              | 722                      | 36 (5.0%)         |
| Anderson <i>et al.</i> ,<br>1997 <sup>36</sup> | 1                | 0                  | 0                           | 1                       | Unclear                        | NR                                     | Yes                              | 295 type 2               | 105 (36%)         |
| Boehm <i>et al.</i> ,<br>2004 <sup>50</sup>    | 2                | 0                  | 1                           | 3                       | Unclear                        | NR                                     | Yes                              | 125                      | 30<br>(24.0%)     |
| Bretzel <i>et al.</i> ,<br>2004 <sup>34</sup>  | 1                | 0                  | 1                           | 2                       | Unclear                        | NR                                     | Yes                              | 231                      | 27<br>(11.7%)     |
| Chan <i>et al.</i> , 2004 <sup>33</sup>        | 1                | 0                  | 0                           | 1                       | Unclear                        | NR                                     | NR                               | 18 type 2                | NR                |
| Gallagher and<br>Home, 2005 <sup>51</sup>      | 2                | 1                  | 1                           | 4                       | Unclear                        | NR                                     | NR                               | 21                       | 3 (14.3%)         |
| Herz <i>et al.</i> , 2002 <sup>37</sup>        | 1                | 0                  | 1                           | 2                       | Unclear                        | NR                                     | Yes                              | 37                       | 4 (10.8%)         |
| Herz <i>et al.</i> , 2003 <sup>38</sup>        | 1                | 0                  | 1                           | 2                       | Unclear                        | NR                                     | Yes                              | 25                       | 4 (16.0%)         |
| Kilo <i>et al.</i> , 2003 <sup>53</sup>        | 1                | 0                  | 1                           | 2                       | Unclear                        | NR                                     | Yes                              | 140                      | 9 (6.4%)          |
| Kokic <i>et al.</i> , 2003 <sup>54</sup>       | 1                | 0                  | 0                           | 1                       | Unclear                        | NR                                     | NR                               | 87                       | NR                |
| Kotsanos <i>et al.</i> ,<br>1997 <sup>39</sup> | 1                | 0                  | 1                           | 2                       | Unclear                        | NR                                     | NR                               | 474 type 2               | 26 (2.8%)         |
| Laube <i>et al.</i> , 1996 <sup>55</sup>       | 1                | 0                  | 0                           | 1                       | Unclear                        | NR                                     | NR                               | 7 type 2                 | 0                 |
| Lourens <i>et al.</i> ,<br>2000 <sup>56</sup>  | 1                | 0                  | 1                           | 2                       | Unclear                        | NR                                     | Yes                              | 45                       | 5 (11.1%)         |
| Niskanen <i>et al.</i> ,<br>2004 <sup>20</sup> | 2                | 0                  | 1                           | 3                       | Adequate                       | NR                                     | Yes                              | 264                      | 8 (3%)            |
| Roach <i>et al.</i> , 1999 <sup>47</sup>       | 1                | 0                  | 1                           | 2                       | Unclear                        | NR                                     | Yes                              | 89                       | 9 (10.1%)         |
| Roach <i>et al.</i> , 1999 <sup>48</sup>       | 1                | 0                  | 1                           | 2                       | Unclear                        | no                                     | Yes                              | 63 type 2                | 3 (3.0%)          |

| Study*   | Jadad score for: |                    |                             | Total<br>Jadad<br>score | Allocation<br>Concealment<br>? | Blinding<br>of<br>Outcome<br>Assessor? | Intent-to-<br>Treat<br>analysis? | Number<br>of<br>Patients | Dropouts<br>N (%) |
|--|------------------|--------------------|-----------------------------|-------------------------|--------------------------------|--|----------------------------------|--------------------------|-------------------|
|  | Randomization    | Double<br>Blinding | Withdrawals<br>and Dropouts |                         |                                |  |                                  |                          |                   |
| Ross <i>et al.</i> , 2001 <sup>41</sup>            | 1                | 0                  | 1                           | 2                       | Unclear                        | NR                                     | Yes                              | 148                      | 5 (3.4%)          |
| Schernthaner <i>et al.</i> ,<br>2004 <sup>32</sup> | 1                | 0                  | 1                           | 2                       | Unclear                        | NR                                     | No                               | 40                       | 5 (12.5%)         |
| Vignati <i>et al.</i> ,<br>1997 <sup>44</sup>      | 2                | 0                  | 1                           | 3                       | Unclear                        | NR                                     | NR                               | 328 type 2               | 29 (4.1%)         |

NR=not reported.

\*Citations of the studies are listed in the main article, available at [www.cmaj.ca/cgi/content/full/180/4/385](http://www.cmaj.ca/cgi/content/full/180/4/385).